gene therapy analysis report discusses all gene therapies under
the broad criteria of genetic material introduced to the cell for a
therapeutic purpose. Detailed discussion on gene therapy pipeline,
its production strategies and main challenges to gene therapy
development is also included in the report. The report will useful
for finding out future prospects and opportunities in Gene
Gene therapy is a medical procedure involving insertion of nucleic
acid polymers in a patient’s cell with the purpose of
preventing or treating genetic diseases. The various approaches
involved are: replacement of the mutated, disease causing gene with
a healthy copy of the gene; inactivation of an improperly
functioning mutated gene; and introduction of a new gene into the
body for treatment of the disease.
therapies have been in development in humans for 25 years, and a
number of products have begun to enter the pharmaceutical market.
However, due to various challenges and clinical trial setbacks,
progress in developing this technology and achieving suitability
for commercial usage has been slow. Gene therapies only account for
a marginal market share and many efficacy and safety concerns
remain unaddressed. However, the pipeline is robust; 906 pipeline
gene therapies are currently in development. Most are at an early
stage of development, with 76% at the Discovery or Preclinical
stage. However, there are currently 23 gene therapy programs in
Phase III development and two at the Pre-registration stage. This
indicates that although gene therapies are beginning to reach the
market after two decades of research in humans, the majority remain
in relatively early development.
Detailed TOC, Tables, Figures, Charts and Companies Mentioned in
“Gene Therapies: A Diverse Range of Technologies with a
Promising Long-Term Outlook” Market Research Report
report provides a comprehensive view of the clinical, R&D,
commercial and competitive landscape of Gene Therapy, and assesses
key developments in delivery vector technology, and challenges and
advances associated with the production of such vectors.
of the Gene therapy analysis report:
25 years of clinical research, only a few gene therapies of all
types have reached the market globally, and none have achieved
strong clinical or commercial success –
Why do gene therapies still occupy only a minimal market share in
their respective indications?
– What can be learned from the gene therapies that have
already reached the market?
A number of different viral and non-viral vector types are
currently in development for the delivery of gene therapies
– What are the relative advantages and disadvantages of each
vector type and which hold the most promise?
– What proportion of the overall gene therapy R&D
pipeline is occupied by each vector type?
current pipeline for gene therapies is diverse in terms of the
approaches and vectors covered; 50% are gene silencing therapies,
while 31% involve the insertion of a functional gene
– In which therapy areas is there the highest level of
R&D activity for gene therapies?
– At which stage of development does the majority of pipeline
gene therapies reside?
– What is the proportion of the pipeline occupied by each
intervention and vector type overall?
A number of companies are currently actively developing pipeline
gene therapies, including private, public and institutional
– How do gene therapies fit into the overall portfolios of
– What is the level of involvement in gene therapy research
from the top 20 Big Pharma companies?
15% Discount on Single User License of Gene Therapies: A Diverse
Range of Technologies with a Promising Long-Term Outlook Market
Research Report at – www.absolutereports.com/enquiry/request-discount/10075327
valid till 1st July 2016
report will allow to –
Understand the current status of the field of therapeutic gene
therapies, and the relative clinical and commercial success of
currently marketed products, comprising Glybera, Kynamro, Macugen,
Vitravene, Gendicine, Oncorine, and Neovasculgen.
Assess the pipeline for gene therapies split by therapy area,
vector type and intervention type, and stage of development.
Additionally, a granular assessment of the pipeline is provided
across the four major therapy areas for gene therapy: oncology,
infectious diseases, central nervous system disorders, and genetic
Gain a picture of the current competitive landscape, with a
detailed breakdown of companies actively involved in the gene
therapy pipeline. Understand the level of involvement on the part
of big pharma companies, and the extent to which gene therapies fit
into the overall portfolios of companies in this field.
Additionally, a highly granular breakdown of companies developing
multiple gene therapies is provided.
Sample of Gene Therapies: A Diverse Range of Technologies with a
Promising Long-Term Outlook Market Research Report
at – www.absolutereports.com/enquiry/request-sample/10075327
Reports is an upscale platform to help key personnel in the
business world in strategizing and taking visionary decisions based
on facts and figures derived from in depth market research. We are
one of the top report resellers in the market, dedicated towards
bringing you an ingenious concoction of data parameters.
+1-408 520 9750
Email – [email protected]